Clinical trial
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving…
NCT00054418 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00054418 |
|---|---|
| Title | Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer |
| Official title | A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Osteoporosis |
| Intervention type | Dietary Supplement, Drug, Other |
| Interventions | calcium carbonate, vitamin D, risedronate sodium, placebo |
| Enrollment | 216 |
| Start date | Mar 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Feb 6, 2003 |
| Last update posted | Jul 13, 2016 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: